Clinical trials: Oral Phase
Head and Neck Cancer
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects of stereotactic radiosurgery in treating…
- Trial name
- NCT00851253
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
Cholera (Disorder)
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity
VAXCHORA (Cholera Vaccine, Live, Oral) is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1.
- Trial name
- NCT03220737
- Testing
- VAXCHORA (Cholera Vaccine, Live, Oral)
- Where
- 10 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Healthy Participants
A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants
The purpose of this study is to determine the pharmacokinetics (PK) of TAK-438 in healthy adult Chinese participants after both single and multiple dose administration.
- Trial name
- NCT03085836
- Testing
- TAK-438
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Takeda
Anemia, End Stage Renal Disease
16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with end stage renal disease undergoing chronic hemodialysis.
- Trial name
- NCT02260193
- Testing
- AKB-6548
- Where
- 16 sites in United States
- Volunteers
- 94 people
- Sponsor
- Akebia Therapeutics
Glioblastoma, MGMT-Unmethylated Glioblastoma
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This Phase I study investigated the side-effects and best dose of microtubule-targeted agent BAL101553 when given together with radiation therapy in treating patients with newly-diagnosed O6-methylguanine-DNA methyltransferase…
- Trial name
- NCT03250299
- Testing
- Microtubule-Targeted Agent BAL101553, Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Basilea Pharmaceutica
Urinary Tract Infection
Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS)
This is a Phase 4, multi-center, open-label, randomized pragmatic superiority clinical trial comparing two strategies for initial or step-down oral therapy for complicated urinary tract infections (cUTI) after 0-48 hours of…
- Trial name
- NCT03697993
- Testing
- Fosfomycin tromethamine, Levofloxacin
- Where
- 12 sites in United States
- Volunteers
- 62 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
Researchers are doing a research study to examine the use of eribulin (eribulin mesylate) in patients with salivary gland cancer. Researchers want to know if eribulin is safe and effective in treating salivary gland cancer.
- Conditions
- Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer
- Trial name
- NCT01613768
- Testing
- eribulin mesylate
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Washington
Chemotherapy-induced Nausea and Vomiting
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intravenous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion…
- Trial name
- NCT03403712
- Testing
- fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
- Where
- 40 sites in United States, Georgia
- Volunteers
- 404 people
- Sponsor
- Helsinn Healthcare SA
Stroke, Atrial Fibrillation
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.
- Trial name
- NCT01671007
- Where
- 522 sites in Austria, Belgium and 20 more
- Volunteers
- 10,471 people
- Sponsor
- Boehringer Ingelheim
Healthy
Bioavailability of Different Applications of Dabigatran in Healthy Volunteers
To determine the relative bioavailability of 150 mg of dabigatran etexilate as pellets on food and of 150 mg of dabigatran etexilate as powder resolved in reconstitution solution, both with 150 mg of dabigatran etexilate as…
- Trial name
- NCT02171611
- Testing
- Dabigatran etexilate pellets, Dabigatran etexilate powder, Dabigatran etexilate capsule
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Acute Myeloid Leukemia
A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML
This study evaluated the efficacy and safety of midostaurin in combination with daunorubicin/cytarabine induction, high dose cytarabine consolidation and midostaurin single agent continuation therapy in newly diagnosed patients…
- Trial name
- NCT03280030
- Testing
- Midostaurin
- Where
- 34 sites in Hong Kong, Japan and 4 more
- Volunteers
- 67 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of milademetan tosylate and to see how well it works with cytarabine with or without ventoclax in treating participants with acute myeloid leukemia that has come back…
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT03634228
- Testing
- Cytarabine, Milademetan Tosylate, Venetoclax
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Leukemia
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma
- Trial name
- NCT00621244
- Testing
- LBH589
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma
The aim of the study is to evaluate efficacy and safety of a 48-week treatment with two doses of tiotropium bromide compared to placebo in adolescent patients with moderate persistent asthma.
- Trial name
- NCT01257230
- Testing
- tiotropium Respimat low dose, tiotropium Respimat high dose
- Where
- 66 sites in United States, Chile and 10 more
- Volunteers
- 398 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus
This is a four-way crossover (non-parallel) study with each subject receiving three of the four arms. The study will enroll approximately 30 adult subjects with T2DM from age 20 to 75 inclusive.
- Trial name
- NCT02954601
- Testing
- ORMD-0801 (qd), ORMD-0801 (bid), ORMD-0801 (tid)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Oramed, Ltd.
Central Nervous System Tumor, Pediatric, Leukemia
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00357500
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 10 sites in United States
- Volunteers
- 101 people
- Sponsor
- Dana-Farber Cancer Institute
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
This phase I trial studies the side effects and determines the best dose of genetically modified neural stem cells and flucytosine when given together with leucovorin for treating patients with recurrent high-grade gliomas.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT02015819
- Testing
- E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Healthy Subjects
Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers
Compare the pharmacokinetics of Dihydroergotamine Mesylate (DHE) delivered by oral inhalation (MAP0004) or Intravenous (IV) DHE in smokers versus non-smokers.
- Trial name
- NCT01199965
- Testing
- MAP0004, IV DHE
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Allergan
Varicella, Rubella
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
The purpose of this study is to assess non-inferiority of two different vaccination regimens using GSK Biological's MMRV vaccine (two doses at 9 and 15 months) or Priorix™ (9 months) and one dose of MMRV vaccine (15 months) to…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00969436
- Testing
- GSK Biological's investigational MMRV vaccine 208136, Priorix™, Varilrix™
- Where
- 6 sites in India
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bronchitis
Crossover, Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup
Objectives: The objectives of the study was to investigate the bioequivalence between two formulations containing S-carboxymethyl-L-cysteine L-lysine monohydrate salt (SCMC-lys) when administered as single oral dose in two…
- Trial name
- NCT02858193
- Testing
- SCMC-lys powder 1.35 g, Fluifort® syrup
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dompé Farmaceutici S.p.A
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.